Thermo Fisher Scientific Inc. has announced the acquisition of Intrinsic Bioprobes Inc. to enhance its work flow for biomarker research and diagnostics. Intrinsic Bioprobes’ portfolio, including its novel mass spectrometric immunoassay, will enable Thermo Fisher to offer its life sciences research and clinical diagnostics customers an enhanced solution for quantitative protein biomarker detection. Intrinsic Bioprobes, based in Tempe, Ariz., manufactures immuno-enrichment, sample-preparation tools used in quantitative mass spectrometry.